Literature DB >> 18434247

Peripheral blood natural killer cells in Crimean-Congo hemorrhagic fever.

Mustafa Yilmaz1, Kemalettin Aydin, Elif Akdogan, Nurgun Sucu, Mehmet Sonmez, Serdar Bedii Omay, Iftihar Koksal.   

Abstract

BACKGROUND: The relationship of changes in the peripheral blood lymphocyte subgroups during Crimean-Congo hemorrhagic fever (CCHF) to prognosis has not been reported.
OBJECTIVES: To determine peripheral blood lymphocyte subgroups in CCHF patients at the time of diagnosis and relate these to clinical outcome. STUDY
DESIGN: Peripheral blood samples were obtained from the patients treated at the Karadeniz Technical University Hospital for CCHF in 2004. Lymphocyte subgroups were analyzed by flow cytometry on these samples and their association with patients' risk group (severe vs. non-severe) and mortality was recorded.
RESULTS: There were significantly more peripheral blood natural killer (NK) cells in severe risk CCHF patients than in non-severe risk group CCHF patients. A positive correlation was found between NK cell count and aspartate transferase (AST), alanine transferase (ALT) and activated partial thromboplastin times (aPTT). In addition, NK cell counts were observed to be higher in two patients who died.
CONCLUSION: Elevated NK cell counts may be a prognostic marker in CCHF patients.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18434247     DOI: 10.1016/j.jcv.2008.03.003

Source DB:  PubMed          Journal:  J Clin Virol        ISSN: 1386-6532            Impact factor:   3.168


  9 in total

1.  Exploring Crimean-Congo Hemorrhagic Fever Virus-Induced Hepatic Injury Using Antibody-Mediated Type I Interferon Blockade in Mice.

Authors:  Michael E Lindquist; Xiankun Zeng; Louis A Altamura; Sharon P Daye; Korey L Delp; Candace Blancett; Kayla M Coffin; Jeffrey W Koehler; Susan Coyne; Charles J Shoemaker; Aura R Garrison; Joseph W Golden
Journal:  J Virol       Date:  2018-10-12       Impact factor: 5.103

2.  Pathogenesis and immune response of Crimean-Congo hemorrhagic fever virus in a STAT-1 knockout mouse model.

Authors:  Dennis A Bente; Judie B Alimonti; Wun-Ju Shieh; Gaëlle Camus; Ute Ströher; Sherif Zaki; Steven M Jones
Journal:  J Virol       Date:  2010-08-25       Impact factor: 5.103

3.  Phenotypic characteristics of natural killer cells in acute hepatitis.

Authors:  Hyosun Cho
Journal:  J Microbiol       Date:  2013-04-27       Impact factor: 3.422

Review 4.  Immunobiology of Crimean-Congo hemorrhagic fever.

Authors:  Sergio E Rodriguez; David W Hawman; Teresa E Sorvillo; T Justin O'Neal; Brian H Bird; Luis L Rodriguez; Éric Bergeron; Stuart T Nichol; Joel M Montgomery; Christina F Spiropoulou; Jessica R Spengler
Journal:  Antiviral Res       Date:  2022-01-11       Impact factor: 10.103

Review 5.  Development of vaccines against Crimean-Congo haemorrhagic fever virus.

Authors:  Stuart D Dowall; Miles W Carroll; Roger Hewson
Journal:  Vaccine       Date:  2017-07-04       Impact factor: 3.641

Review 6.  Crimean-Congo Hemorrhagic Fever: Tick-Host-Virus Interactions.

Authors:  Anna Papa; Katerina Tsergouli; Katerina Tsioka; Ali Mirazimi
Journal:  Front Cell Infect Microbiol       Date:  2017-05-26       Impact factor: 5.293

Review 7.  Natural killer cell responses to emerging viruses of zoonotic origin.

Authors:  Carlos Diaz-Salazar; Joseph C Sun
Journal:  Curr Opin Virol       Date:  2020-08-09       Impact factor: 7.090

Review 8.  Interferon and cytokine responses to Crimean Congo hemorrhagic fever virus; an emerging and neglected viral zonoosis.

Authors:  Friedemann Weber; Ali Mirazimi
Journal:  Cytokine Growth Factor Rev       Date:  2008-11-21       Impact factor: 7.638

9.  Fluorescent Crimean-Congo hemorrhagic fever virus illuminates tissue tropism patterns and identifies early mononuclear phagocytic cell targets in Ifnar-/- mice.

Authors:  Stephen R Welch; Jana M Ritter; Anita K McElroy; Jessica R Harmon; JoAnn D Coleman-McCray; Florine E M Scholte; Gary P Kobinger; Éric Bergeron; Sherif R Zaki; Stuart T Nichol; Jessica R Spengler; Christina F Spiropoulou
Journal:  PLoS Pathog       Date:  2019-12-02       Impact factor: 6.823

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.